Document x19KrKEOjxBw0rqJkYZqR3x70

>fT OPPTNCIC 2083 APR 27 PH 2- US i a <7? NAME ORGANIZATION TELEPHONE # E-MAIL ADDRESS --------------3 r 5-o--a--ti - --*--J-U---------------------- B P fi/o p rr /& y > k \< \ V nW < U J -i ? 5?X 4 T C f /(A 5rji A SaU i c?D#-S'b`/-$ tO < / A ovAi #.\a U . 'a)&pa., a^ai/ o A r t - m s 9 ( 2 , 0 (la O .n / r y V i'S fa z 7*7/ r ^ i tv' < 2 //**<* - c ^-v. Q*~ ?j / - 5 U '^ v - (2 o v i^ 2 < 0O' f ~Z- / vZAaJM^ /(?/Z 7 ~<D/Z f L a n o M c - s e r H Pecker-fay / e s r o / m 7 a S 5 6 i t - S s H c h J d a ^ d d L Q & zfn . i / AT2?A/aJA dpt&/>1/CAL6 '2 . t S - H l `1-702S r&A k ' i b v - i ? p i r i c i (?& ttrP /n & * S qls/ A ^ S o l E-)((S BPA/OPPJ /CCJ> 15 6 -? -';I ' M } ; peZ-dsl- $ 0 iq ^ s&9 2 m l a i it(2 , m t b z p f a & i/av . co w\ ! Virginia.. h \j \oe r 2 ($<60 / 1/4v * Cx)/>7 ;/ penberTh y wa+d ^ov ^ r-J L U ?* ^ P '-- O ^ A z /V U M & 2 Ptyl qiC(?t P > effl /om/iift-t) pP^h/6 ?VT/1 2 AO >,,,,3- i f k i 8 n 7o za-rw m M H 1-0 ? - 2 (o2 - a l j o oebor, `J & P 5c'f <s/ tJ !~^C * fP'- .(u-J A^aiA'Pi, 095ar 6 ' e ^ - S*v/ ^AO-iA.\bLVy^. ^rvvWsJOtSCKW ?A, /06jC lO2 - 5 t V 5 t K \ - -P-Adk/ /\ M f\ vA A M 1/ / f ^ i o ? n O p - n T O X - W 8 5 5 ? ^ l* c - *K <twfo tf, <lv4y<^u2.P`\ - 5 d / i ^ f t 4 /W ilSrO 'N / e p a U y p p r/c a ) 1 //> ^/>i, 099L4) a-pa , 10 V (fp rh /L r^ U t^ fts i^ \ ^PPloPpriooA) i/ (W , ^ < l k %jk ^ Uajjj ru b (, ^ b c r L , (>j r o t r a y s ' 5 "A f sc , .C^ w ^ u 1 14 t f p i > u z 1. L-A9<->i'< >^.c_ <1 1 L.'A><z/c-> - > i c\ s ft e, frx v^r& n o f(T /p e w /c m (( -M /< z -ro /& A 3> E f \ foPFT f e e d / a (\-rX'A9`n . A) 2 0c\, <&\'u\/ ( rJ 2 J 3 2 - ' ^ ' / ' ^ S 5 ^ / / / 6 c J o . / c J i-e /o c - . AP$ Ar-Oiy A - / //T - f a m n . l p H -y lfz jrt1 ep* . qo{/ i APFN Work Group Presentation to EPA January 16, 2003 "COMPANY SANITIZED. DOES NOT CONTAIN TSCA CBI" Agenda <rBackground What is the APFN Work Group? Relationship with FMG What is APFN and what is it used for? r Analytical Methods Development r Toxicology and Environmental Program Current Knowledge of APFN Ongoing toxicology/ecotoxicology program r Summary Fluoropolymer Manufacturers Group (FMG) r The mission of the FMG is to promote the continued safe manufacture and use of fluoropolymers made using fluoropolymer polymerization aids (FPA) while establishing and supporting responsible use of fluoropolymer products and minimizing the impact on the environment What is the APFN Work Group? r Separate SPI Work Group r Formed to evaluate APFN as compared to APFO f Members are producers and users of APFN Limited number of participants complicates the sharing of some information 3 APFN Work Group Members r Asahi Glass Co. Ltd. r Atofina Chemicals, Inc. ir Solvay Solexis, Inc. (Ausimont) What is APFN? r APFN is one of the FPAs used by the FMG member companies to produce fluoropolymers as reported in the FMG mass balance update in Sept. 2002 r FPA - Fluoropolymer polymerization aide commercially available perfluoroalkyl carboxylate surfactant H 3 Commercially Available APFN r CAS number 72968-3-88 CBI redacted Use of Commercial APFN CBI redacted PVDF Applications r Handled only in industrial processes Highly weatherable architectural coatings Ultrapure water systems in semiconductor and pharmaceutical industries Handling of corrosive chemicals - pipes, filter media, tanks, etc. Fire resistant electrical insulation Lithium ion batteries ** No direct consumer applications Fluoropolymer Manufacturing Group Point Source Emissions Include APFN r Voluntary worldwide commitment to contain Global minimum emissions reduction of 50% Base year '99 or '00 Goal years 2004 - 2006 r Emissions reduction forecast completed 49% Reduction by 2004 67% Reduction by 2006 6 5 Analytical Methods Development r Method development and validation underway at CRO Selected laboratory experienced with this family of chemistry Provide quantitation at ppb - ppt levels r Three matrices: -Water (LC/MS/MS) -Serum (LC/MS/MS) -Air (LC/MS) Analytical Methods Development r Methods developed r Validation in progress r Timing of validation Water: completed November 2002 to coincide with toxicology testing Serum: completed December 2002 Air: January 2003 7 6 APFN Toxicology Data Acute Animal toxicity data in literature * LC50 4 hr. inhalation - rat: 820 mg/m3 * ALD oral - rat: 187 mg/kg Repeated dose oral toxicity - mouse * Dietary exposure - 14 days * Increased liver weight - males > 1 ppm; females > 3 ppm * Lethality > 300 ppm females; > 3000 ppm males Commercial APFN LD50 oral - mouse: 500 - 2000 mg/kg r15% aa. solnl * Ames Test - Negative Comparison of FPA Data Acute oral, rat Com m ercial and purified APFO LD50 540 mg/kg Acute derm al, rat 4 hr inhalation, rat G e n o to x icity Target organs Peroxisom e proliferator M etabolized in v iv o Biodegradation W ater solubility LD50 6959 mg/kg LC50 980 mg/m3 Not m utagenic Liver, pancreas, testes Yes No No - very low >10% Com m ercial and purified APFN PFDA ALD 187 mg/kg LD 50:500 - 2000 ( m ou se 15% aa soin) ALD 96 mg/kg LC50 820 mg/m3 Not m utagenic Liver (lim ited data) Yes Not expected Not expected >10% Not m utagenic Liver, testes, thym us Yes No Not expected APFN Testing Strategy Determine differences and similarities of commercial APFN and APFO Use screening approach to begin 3 Proposed studies Chemical/physical properties Health effects Environmental effects APFN Studies Planned r Physical/chemical properties * Vapor pressure * Water solubility * Stability in water (hydrolysis as a function of pH) r Health effects * Acute oral toxicity in rats * 28 day oral study with reproduction screen (rats) f Environmental effects * Acute studies in fish, daphnia, algae APFN Testing Status r Water method completed Nov. 2002 r 28 day oral study started at TNO in 4th Quarter 2002 Doses selected are 0.1, 0.5, and 2 mg/kg Anticipate results 2nd quarter 2003 Preliminary range finding results were reported to TSCA 8(e) office Dec 20, 2002 r Environmental effects and phys/chem properties testing initiated Summary f APFN not widely used Limited mostly to PVDF manufacturing r Primarily industrial applications; No direct consumer applications r Significant reduction in potential exposure sources planned Emissions at fluoropolymer plants r Toxicity and environmental effects work progressing on schedule IO 9